EECP vs. Stenting: What Patients With Angina Need to Know
If you have chronic stable angina, you've probably been offered a stent. You may not have been offered EECP. Here's what the evidence actually says about both — and why that gap exists.
The problem with how angina is treated
Chronic stable angina — chest tightness or pressure that occurs with exertion and resolves with rest — affects millions of Americans. The standard treatment pathway is medications first, then stenting or bypass surgery if medications don't control symptoms adequately. EECP is rarely mentioned, despite having FDA clearance for angina and strong clinical evidence. This guide explains why that gap exists and what it means for patients.
How stenting works
A coronary stent is a small metal mesh tube inserted into a narrowed or blocked coronary artery to hold it open. The procedure — percutaneous coronary intervention (PCI) — is performed under sedation, typically takes 30–60 minutes, and requires a short hospital stay. Stenting is highly effective at relieving the mechanical obstruction that causes angina in the treated vessel. It does not, however, address the underlying disease process — atherosclerosis — or improve circulation in vessels that weren't stented.
The ORBITA trial (2017) found that stenting for stable angina provided no greater improvement in exercise capacity or angina frequency than a sham procedure at 6 weeks. This finding was controversial and debated, but it raised important questions about the magnitude of benefit from stenting in stable (non-acute) presentations.
How EECP works
EECP doesn't open a specific blocked artery. Instead, it improves circulation throughout the coronary system by promoting the development of collateral blood vessels — natural bypasses that route blood around blockages. It also improves endothelial function (the health of the artery lining), reduces arterial stiffness, and increases nitric oxide production. These effects are systemic, not limited to a single vessel.
What the evidence shows for each
For acute coronary syndromes — heart attacks, unstable angina — stenting is clearly superior and often life-saving. The evidence for stenting in stable angina is more nuanced. For EECP in stable angina, the MUST-EECP trial demonstrated significant reductions in angina frequency and improvements in exercise tolerance compared to sham treatment. Medicare covers EECP for stable angina under National Coverage Determination 20.20.
- →Acute coronary syndromes: Stenting is the clear standard of care
- →Stable angina: Both stenting and EECP have evidence; stenting has more procedural risk
- →EECP: No procedural risk, no recovery time, systemic benefits beyond the treated area
- →Stenting: Immediate mechanical relief, but doesn't address disease progression
- →EECP: Benefits continue building for 4–8 weeks after the course ends
The risk profiles are very different
Stenting carries procedural risks including bleeding, arterial injury, contrast nephropathy, and stent thrombosis. In-stent restenosis (re-narrowing) occurs in 5–10% of patients with drug-eluting stents. Patients require dual antiplatelet therapy for 6–12 months post-procedure, which carries its own bleeding risk. EECP has no procedural risk. The most common adverse effects are mild skin irritation from cuff contact and occasional fatigue in the first week of treatment. There are no long-term side effects.
Why EECP is underused
EECP is underused for several reasons. It requires 35 hours of treatment — a significant time commitment compared to a single stenting procedure. It doesn't generate the same reimbursement as interventional procedures. Most cardiologists were not trained in EECP and are unfamiliar with the evidence base. And the therapy lacks the dramatic immediacy of a procedure — patients don't feel better the day after their first session the way they might after a stent.
The bottom line for patients
If you have an acute coronary syndrome — a heart attack or unstable angina — stenting is likely the right choice and you should not delay. If you have chronic stable angina that is managed with medications, EECP is a legitimate evidence-based option that most patients have never been offered. It's worth a conversation with a provider who knows the evidence.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. EECP therapy should be considered in consultation with a qualified healthcare provider who can evaluate your individual clinical situation. Atlantic EECP does not provide diagnosis or treatment recommendations without a clinical evaluation.
Jack Clifford's definitive patient guide — the science, the history, the politics, and the practical reality of EECP. The book I wish I'd had in that hospital bed.